Novo Nordisk CEO says investors still underestimate the company a year into its turnaround

A year into his tenure as CEO of Novo Nordisk, Mike Doustdar is leading a corporate turnaround at the maker of Ozempic. Investors remain nervous about the company's future prospects, but Doustdar argues that markets are still underestimating the promise of its drug portfolio.